The verdict
Our read at a glance.
Whether vosoritide's approved benefit is understood as increasing growth velocity in children with achondroplasia who still have open growth plates, while the question of whether it improves final adult height and the medical complications of achondroplasia is still maturing.
- The signal
- A randomized placebo-controlled trial and its long-term extensions show vosoritide increases yearly growth velocity in children with achondroplasia who have open growth plates, by roughly 1.5 cm per year over the first year, with growth maintained over longer follow-up.
- The unknown
- Whether faster growth translates into greater final adult height and, more importantly, fewer of achondroplasia's medical complications (such as spinal and skull-base narrowing and sleep apnea), and how meaningful the gains are for daily life. Growth velocity was the trial endpoint, not those longer-term outcomes.
- Our read
- A genuine first: vosoritide targets the root signaling defect of achondroplasia and clearly speeds up growth in children with open growth plates. The open question is what that faster growth ultimately buys, more final height and fewer complications, or mainly a change in growth velocity, which longer-term data are still working out.
The mechanism
How it works.
Achondroplasia is caused by an overactive version of a receptor called FGFR3, which acts like a brake on the cartilage cells in the growth plates at the ends of bones, so the bones grow less. Vosoritide is a lab-made, longer-lasting version of a natural signaling peptide called C-type natriuretic peptide (CNP). It binds a receptor (NPR-B) on those same growth-plate cells and switches on a counter-signal that eases the FGFR3 brake, letting the cartilage cells grow and multiply more normally. Native CNP is broken down within minutes; vosoritide is engineered to resist that breakdown so a daily injection can keep the signal going. The natural CNP system also relaxes blood vessels, which is why the drug can briefly lower blood pressure.
Safety & regulatory boundary
The consequential part.
Vosoritide is given as a daily injection and can briefly lower blood pressure (the natriuretic-peptide family relaxes blood vessels), so children should eat and drink beforehand; injection-site reactions are common. It is approved specifically for achondroplasia in children with open growth plates, not for idiopathic short stature or other causes of short stature. Voxzogo is a prescription drug used under specialist care.
What's next
What we're watching.
Final adult-height data, whether the medical complications of achondroplasia improve, results in very young children, and how families and clinicians weigh the benefits against daily injections.
Context
Why this is discussed.
Vosoritide is the first drug aimed at the underlying biology of achondroplasia, the most common form of short-limbed dwarfism. Instead of treating complications, it targets the overactive signal in the growth plate that holds bone growth back, and in trials it made children grow faster.
The evidence base
21 cited references.
Regulatory & labels1
BioMarin Pharmaceutical Inc. (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · PHASE2/PHASE3 · RECRUITING · 2026-04
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-10-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-11-22
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-07-30
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2020-08-04
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2016-01-26
ClinicalTrials.gov · PHASE3 · ACTIVE_NOT_RECRUITING · 2017-12-12
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2019-06-12
Indexed literature (PubMed)12
Savarirayan R et al. · Lancet Child Adolesc Health · 2024
Murton MC et al. · Adv Ther · 2023
Nicolae R et al. · Curr Opin Pediatr · 2025
Savarirayan R et al. · Lancet · 2020
Jones HL et al. · Cureus · 2025
Savarirayan R et al. · Genet Med · 2021
Savarirayan R et al. · Nat Rev Endocrinol · 2025
Merchant N et al. · J Clin Endocrinol Metab · 2025
Wrobel W et al. · Int J Mol Sci · 2021
Savarirayan R et al. · Med · 2025
PubMed · 2012
Duggan S · Drugs · 2021
Keep reading